<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 · Science · 4,427 citations
https://doi.org/10.1126/science.1141478
J
James G. Christensen
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
983
Papers
45.8K
Citations
86
h-index
173
i10-index
James G. Christensen is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Colorectal Cancer Treatments and Studies & HER2/EGFR in Cancer Research. The author has an h-index of 86, co-authored 836 publications.
ORCID: 0000-0003-1835-0335Papers by this author
worksGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
2011 · Science Translational Medicine · 3,511 citations
https://doi.org/10.1126/scitranslmed.3002003
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
2019 · Cancer Discovery · 1,249 citations
https://doi.org/10.1158/2159-8290.cd-19-1167
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
2022 · New England Journal of Medicine · 886 citations
https://doi.org/10.1056/nejmoa2204619
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor
2021 · Journal of Medicinal Chemistry · 644 citations
https://doi.org/10.1021/acs.jmedchem.1c01688
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
2022 · Nature Medicine · 465 citations
https://doi.org/10.1038/s41591-022-02007-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat